PDF(Pubmed)
Abstract：
Stem cell therapies can potentially treat various retinal degenerative diseases, including age-related macular degeneration (AMD) and inherited retinal diseases like retinitis pigmentosa. For these diseases, transplanted cells may include stem cell-derived retinal pigmented epithelial (RPE) cells, photoreceptors, or a combination of both. Although stem cell-derived RPE cells have progressed to human clinical trials, therapies using photoreceptors and other retinal cell types are lagging. In this review, we discuss the potential use of human pluripotent stem cell (hPSC)-derived photoreceptors for the treatment of retinal degeneration and highlight the progress and challenges for their efficient production and clinical application in regenerative medicine.
摘要：
干细胞疗法可以治疗各种视网膜退行性疾病，包括年龄相关性黄斑变性（AMD）和遗传性视网膜疾病，如视网膜色素变性。对于这些疾病,移植细胞可能包括干细胞衍生的视网膜色素上皮细胞（RPE），光感受器，或两者的组合。尽管干细胞来源的RPE细胞已经发展到人类临床试验，使用光感受器和其他视网膜细胞类型的治疗滞后。在这次审查中,我们讨论了人类多能干细胞（hPSC）衍生的光感受器在治疗视网膜变性中的潜在用途，并强调了其在再生医学中的有效生产和临床应用的进展和挑战。
